Bli medlem
Bli medlem

Du är här

2016-05-06

BioInvent: BioInvent's Board Director Dharminder Chahal increases his shareholding in the company

Lund, Sweden - 6 May - BioInvent International (BINV) today announced
that Mr. Dharminder Chahal has increased his shareholding in
BioInvent by the acquisition of 13,980,000 shares. Following the
transaction, Mr. Chahal holds 14,206,148 shares, corresponding to
5.02 percent of the outstanding shares and votes in BioInvent. Prior
to this transaction, Mr. Chahal held 226,148 shares in the company.

Dharminder Chahal is a Board Director of BioInvent since 2013.

To the editors:

About BioInvent
BioInvent International AB develops immune oncology drugs. With one of
the world's largest antibody libraries, and a unique, proprietary
discovery method, BioInvent can identify the optimal cellular targets
and antibodies for the treatment of various tumor types. BioInvent
has also considerable experience in, and a facility for, process
development and production of antibodies for clinical studies. This
makes it possible to develop proprietary drug projects and also to
supply leading international pharmaceutical companies with effective
tools for their drug development. BioInvent currently has three
proprietary projects in or close to clinical development and
partnership agreements with seven global pharmaceutical and biotech
companies. More information is available at www.bioinvent.com.

For further information, please contact:
Michael Oredsson
President and CEO
+46 (0)46 286 85 67
+46 (0)70716 89 30
michael.oredsson@bioinvent.com

BioInvent International AB (publ)
Co. reg. No: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46(0)46 286 85 50
info@bioinvent.com
www.bioinvent.com

The press release contains statements about the future, consisting of
subjective assumptions and forecasts for future scenarios.
Predictions for the future only apply as of the date they are made
and are, by their very nature, in the same way as research and
development work in the biotech segment, associated with risk and
uncertainty. With this in mind, the actual outcome may deviate
significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein
pursuant to the Swedish Securities Markets Act and/or the Swedish
Financial Instruments Trading Act. The information was submitted for
publication at 8.40 a.m. CET, on 6 May 2016.

-----------------------------------------------------------
http://feed.ne.cision.com/client/waymaker1/WOLReleaseFile.aspx?id=350994...
http://mb.cision.com/Main/583/2003647/512019.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.